Actively Recruiting
Postpartum Evaluation of Nifedipine and Enalapril for Hypertension
Led by Nebraska Methodist Health System · Updated on 2025-10-22
850
Participants Needed
1
Research Sites
177 weeks
Total Duration
On this page
Sponsors
N
Nebraska Methodist Health System
Lead Sponsor
M
Methodist Hospital Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine. Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study. The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.
CONDITIONS
Official Title
Postpartum Evaluation of Nifedipine and Enalapril for Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Admitted for delivery by cesarean or vaginal delivery
- Pregnancy of 24 weeks gestation or greater
- Diagnosis of pregnancy-related hypertension or chronic hypertension, with pregnancy-related hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on two occasions at least 4 hours apart
You will not qualify if you...
- Absolute contraindication to either nifedipine or enalapril
- Persistent heart rate less than 60 or greater than 110
- Native language other than English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Methodist Women's Hospital
Omaha, Nebraska, United States, 68022
Actively Recruiting
Research Team
T
Todd Lovgren, MD
CONTACT
J
Joshua Dahlke, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here